Credit Suisse Ag Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $1.14 Million - $1.57 Million	8,900 Added 28.08%	40,600 $6.88 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $3.79 Million - $5.25 Million	29,900 Added 1661.11%	31,700 $4.48 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $8.87 Million - $12.1 Million	-73,200 Reduced 97.6%	1,800 $262,000
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $25.8 Million - $37.1 Million	-276,700 Reduced 78.68%	75,000 $8.16 Million
Q4 2018 Feb 13, 2019	BUY	$62.67 - $88.33 $22 Million - $31.1 Million	351,700 New	351,700 $25.6 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.